Molecular Imaging in Breast Cancer.

Breast cancer Molecular imaging Personalized medicine Positron emission tomography Precision oncology

Journal

Nuclear medicine and molecular imaging
ISSN: 1869-3474
Titre abrégé: Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101530478

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 08 07 2019
revised: 26 08 2019
accepted: 10 09 2019
entrez: 15 11 2019
pubmed: 15 11 2019
medline: 15 11 2019
Statut: ppublish

Résumé

Breast cancer (BC) is the most common cancer among females with more than 2 million new cases diagnosed worldwide in 2018. Although the prognosis in the majority of cases in the early stages combined with appropriate treatment is positive, there are still about 30% of patients who will develop locoregional diseases and distant metastases. Molecular imaging is very important in the diagnosis, staging, follow-up, and radiotherapy planning. Additionally, it is useful in characterizing lesions, prognosis, and therapy response in BC patients. Nuclear medicine imaging modalities (SPECT and PET) are of indispensable importance in diagnosis (positron emission mammography), staging (sentinel lymph node detection), and follow-up with

Identifiants

pubmed: 31723360
doi: 10.1007/s13139-019-00614-w
pii: 614
pmc: PMC6821902
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

313-319

Informations de copyright

© Korean Society of Nuclear Medicine 2019.

Déclaration de conflit d'intérêts

Conflict of interestDaniela Miladinova declares no conflict of interest.

Références

J Nucl Med. 2017 Dec;58(12):1906-1912
pubmed: 28912144
Breast Care (Basel). 2012 Oct;7(5):408-10
pubmed: 24647781
Int J Nanomedicine. 2017 May 02;12:3447-3461
pubmed: 28496321
J Nucl Med. 2013 Nov;54(11):1869-75
pubmed: 24029656
Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1482-3
pubmed: 25931036
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):689-694
pubmed: 27822700
Clin Cancer Res. 2017 Jan 15;23(2):407-415
pubmed: 27342400
J Nucl Med. 2017 Apr;58(4):563-568
pubmed: 27688475
PLoS One. 2016 Dec 19;11(12):e0168248
pubmed: 27992512
J Nucl Med. 2017 May;58(5):821-826
pubmed: 28104744
Theranostics. 2016 Jun 19;6(10):1641-50
pubmed: 27446498
Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1339-47
pubmed: 17333178
J Nucl Med. 2014 May;55(5):730-5
pubmed: 24665085
Ann Nucl Med. 2016 Feb;30(2):130-7
pubmed: 26586370
N Engl J Med. 1981 Jul 2;305(1):6-11
pubmed: 7015141
J Nucl Med. 2016 Feb;57 Suppl 1:9S-16S
pubmed: 26834110
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1937-44
pubmed: 27129866
J Nucl Med. 2017 Apr;58(4):560-562
pubmed: 27856629
Am J Pathol. 2013 Oct;183(4):1113-1124
pubmed: 23993780

Auteurs

Daniela Miladinova (D)

Institute of Pathophysiology and Nuclear Medicine Academician Isak S.Tadzer, Faculty of Medicine, University Ss. Cyril and Methodius in Skopje, Mother Theresa 17, 1000 Skopje, North Macedonia.

Classifications MeSH